UCB dedicated Georgia site. UCB stock sits below EUR 206.70
Published on 10/12/2026 at 09:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- UCB dedicated its Georgia biologics campus on October 10, 2026, adding a 460,000-square-foot manufacturing site.
- First-half 2026 revenue reached EUR 4.27 billion, up 22.00 percent year over year.
- UCB stock was trading at EUR 205.15 at Lang & Schwarz on October 12, 2026, 0.75 percent below the October 9 Xetra close of EUR 206.70.
- Barclays maintained a Hold rating and a EUR 260.00 price target on October 2, 2026.
UCB dedicated its new Georgia biologics campus on October 10, 2026, while UCB stock was trading below the EUR 206.70 Xetra close of October 9. Morningstar reported that the facility is designed to cover 460,000 square feet and support commercial biologics production.
Three milestones shape the story
On July 31, 2026, UCB reported first-half revenue of EUR 4.27 billion, up 22.00 percent from the comparable period. The company's investor page also lists BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7.00 billion. On September 29, 2026, UCB presented data from its neurology portfolio at scientific meetings, according to Ideal Investisseur. The latest milestone came on October 10, 2026, with the Georgia site dedication and its 460,000-square-foot design.
What does the Georgia site add?
The campus gives UCB a new commercial biologics manufacturing base in the United States, linking production capacity with the company's growth portfolio. That matters because BIMZELX generated EUR 1.52 billion in first-half 2026 sales, while UCB's peak sales guidance for the medicine is above EUR 7.00 billion, according to UCB.
The market's valuation reference is more measured. On October 2, 2026, Barclays maintained a Hold rating on UCB and set a EUR 260.00 price target, as reported by Markets Insider. The target is EUR 54.85 above the October 12 Lang & Schwarz price, but the two figures come from different reference points and are not a trading forecast.
Next date for UCB results
UCB is scheduled to report fiscal year 2026 results on February 25, 2027, according to Simply Wall St. Until then, the Georgia investment and the next readout on product growth remain the clearest operating markers for the stock.
UCB stock stays below the Xetra close
UCB stock was trading at EUR 205.15 at Lang & Schwarz on October 12, 2026 at 9:07 a.m. CEST, down 0.75 percent versus the Xetra close of October 9, 2026 at EUR 206.70. The company had a market capitalization of EUR 38.7 billion as of October 9, 2026, and its 52-week range was EUR 198.75 to EUR 289.50.
The further course of trading is shown by the continuously updated real-time quote of UCB stock.
UCB stock facts
- Company: UCB S.A.
- ISIN: BE0003739530
- Ticker: UCB
- Primary exchange: Euronext Brussels
- Price Lang & Schwarz (as of October 12, 2026, 9:07 a.m. CEST): EUR 205.15
- Change versus Xetra close: minus 0.75 percent
- Xetra close (October 9, 2026): EUR 206.70
- Market capitalization: EUR 38.7 billion (as of October 9, 2026)
- 52-week range: EUR 198.75-EUR 289.50
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: BEL 20
- Next earnings date: February 25, 2027
Market context: Market report Euro Stoxx 50.
